Friday, December 9, 2022, 3:15 PM – 5:15 PM CT (4:15 PM – 6:15 PM ET) – New Orleans, Louisiana

Addressing Current Questions and Controversies in the Management of Hodgkin and Non-Hodgkin Lymphoma — What Clinicians Want to Know (Part 2 of a 3-Part Series)

A CME Friday Satellite Symposium and Virtual Event Preceding the 64th ASH Annual Meeting

Location
Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113
Hotel Phone: (504) 561-1234

Program Schedule — Central Time
3:00 PM – 3:15 PM — Registration and Snacks
3:15 PM – 5:15 PM — Educational Meeting

Meeting Room
Celestin Ballroom ABCD (Level 3)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in New Orleans, preregistration is required as seating is limited.  
 
Faculty
Jonathan W Friedberg, MD, MMSc
Samuel E Durand Professor of Medicine
Director, James P Wilmot Cancer Institute
University of Rochester
Rochester, New York

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

David G Maloney, MD, PhD
Professor, Clinical Research Division
Medical Director
Cellular Immunotherapy and Bezos Family Immunotherapy Clinic
Leonard and Norma Klorfine Endowed Chair for Clinical Research
Fred Hutchinson Cancer Center
Professor of Medicine, Division of Oncology
University of Washington
Seattle, Washington


Loretta J Nastoupil, MD
Associate Professor
Section Chief, Indolent Lymphoma
Section Chief, New Drug Development
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Sonali M Smith, MD
Elwood V Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Co-Leader, Cancer Service Line
Co-Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Kite, A Gilead Company, MEI Pharma Inc, Novartis, and Seagen Inc.
Program Schedule — Central Time
3:00 PM – 3:15 PM — Registration and Refreshments
3:15 PM – 5:15 PM — Educational Meeting

MODULE 1: Diffuse Large B-Cell Lymphoma (DLBCL)

  • Improvement in progression-free survival reported in the Phase III POLARIX study comparing polatuzumab vedotin in combination with chemoimmunotherapy to R-CHOP for previously untreated DLBCL; implications for practice
  • Available data with and ongoing and planned evaluation of other novel agents for DLBCL in the first-line setting (eg, tafasitamab, loncastuximab tesirine, CC-486)
  • Published research findings with polatuzumab vedotin in combination with bendamustine/rituximab for relapsed/refractory (R/R) DLBCL; optimal incorporation into current management algorithms
  • Major efficacy and safety data with tafasitamab/lenalidomide for R/R DLBCL; current role in clinical practice
  • Loncastuximab tesirine in comparison to other approved regimens: Mechanism of action, available data and optimal sequencing
  • Available efficacy and safety data with selinexor for R/R DLBCL; practical implementation and patient selection
  • Available data with and ongoing and planned evaluation of novel bispecific antibodies for DLBCL

MODULE 2: Follicular Lymphoma (FL)

  • Appropriate integration of obinutuzumab into current FL treatment algorithms; practical implications of the Phase IV GAZELLE study demonstrating the efficacy and safety of a shorter, 90-minute infusion
  • Long-term clinical trial findings with lenalidomide/rituximab for treatment-naïve and R/R FL; current role in practice
  • Key efficacy and safety findings from the Phase III CHRONOS-3 trial evaluating copanlisib in combination with rituximab for R/R FL
  • Current clinical utility of PI3 kinase inhibitors in the treatment of R/R FL; implications of the withdrawal of indications for idelalisib, umbralisib and duvelisib
  • Incidence of EZH2 mutations in patients with FL; key findings with and optimal use of tazemetostat for previously treated FL with and without EZH2 mutations
  • Mechanism of action of and available safety and efficacy data with investigational bispecific antibodies for R/R FL (eg, mosunetuzumab, glofitamab, epcoritamab); FDA breakthrough therapy designation for mosunetuzumab and potential role in practice
  • Early results with and ongoing investigation of other novel agents and strategies for FL

MODULE 3: Hodgkin Lymphoma (HL)

  • Long-term follow-up, including overall survival findings, from the Phase III ECHELON-1 trial; selection of patients with advanced classical HL for first-line brentuximab vedotin (BV) in combination with AVD (doxorubicin/vinblastine/dacarbazine)
  • Early findings with BV combined with chemotherapy for early-stage, unfavorable-risk HL
  • Available data with and current role of BV in therapy for older patients with newly diagnosed advanced HL
  • Potential role of BV alone or in combination with immune checkpoint inhibition as a bridge to transplant for patients experiencing disease progression on up-front treatment
  • Key efficacy and safety findings from the Phase III KEYNOTE-204 trial evaluating pembrolizumab versus BV for R/R HL; implications for clinical practice
  • Published efficacy and safety findings with and ongoing evaluation of anti-PD-1/PD-L1 antibodies in combination with other systemic approaches (eg, BV, chemotherapy)
  • Other promising investigational strategies for patients with HL (eg, camidanlumab tesirine, CAR T-cell therapy)

MODULE 4: Chimeric Antigen Receptor (CAR) T-Cell Therapy for Non-Hodgkin Lymphoma (NHL)

  • Long-term efficacy and safety findings with axicabtagene ciloleucel (axi-cel), tisagenlecleucel and lisocabtagene maraleucel (liso-cel) for patients with multiregimen-relapsed DLBCL
  • Available results from Phase III studies evaluating CAR T-cell therapy as second-line treatment for DLBCL (eg, TRANSFORM, ZUMA-7, BELINDA); recent FDA approval of axi-cel in this setting and appropriate identification of candidates for this strategy
  • Published results from the ZUMA-12 study evaluating axi-cel as first-line therapy for high-risk large B-cell lymphoma
  • Key clinical research findings with and optimal integration of brexucabtagene autoleucel into current mantle cell lymphoma (MCL) treatment algorithms; ongoing assessment of other CAR T-cell platforms for MCL (eg, liso-cel)
  • Principal outcomes from pivotal studies evaluating CAR T-cell therapy for FL (eg, ZUMA-5, ELARA); FDA approval of axi-cel and current role in clinical practice

MODULE 5: Mantle Cell Lymphoma (MCL)

  • Research database supporting the FDA approvals of ibrutinib, acalabrutinib and zanubrutinib for R/R MCL; key factors in choosing a Bruton tyrosine kinase (BTK) inhibitor and practical use of these agents
  • Activity and safety data with and ongoing Phase III investigations of BTK inhibitors alone or in combination with other systemic therapies for previously untreated MCL; current and potential clinical role
  • Mechanisms of resistance to BTK inhibition; efficacy and safety findings from the Phase I/II BRUIN study of the noncovalent BTK inhibitor pirtobrutinib for R/R MCL
  • Available data with, current nonresearch role of and ongoing trials assessing venetoclax alone or combined with other agents for MCL
  • Ongoing investigation of other novel agents and strategies for MCL

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand published research data informing the selection, sequencing and combining of available therapeutic agents in the nonresearch care of patients with previously untreated or relapsed/refractory (R/R) follicular lymphoma (FL).
  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential utility of those therapies in clinical practice.
  • Consider patient age, performance status and other clinical and biologic factors in the selection of up-front and subsequent therapy for mantle cell lymphoma (MCL).
  • Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Assess available clinical trial findings informing the utilization of CD19-directed CAR (chimeric antigen receptor) T-cell therapy for R/R DLBCL, MCL and FL, and counsel appropriately selected patients regarding the potential benefits of this strategy.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for FL, DLBCL, MCL and HL to support quality of life and continuation of treatment.
  • Recall new data with agents and strategies currently under investigation for HL and various forms of non-Hodgkin lymphoma, and discuss ongoing trial opportunities with eligible patients.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Kite, A Gilead Company, MEI Pharma Inc, Novartis, and Seagen Inc.

Location
Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113
Phone: (504) 561-1234

Meeting Room
Celestin Ballroom ABCD (Level 3)

Directions
Hyatt Regency New Orleans is conveniently located 6 minutes (1.1 miles) from the Ernest N Morial Convention Center, where the 64th ASH Annual Meeting is taking place. ASH will be providing complimentary shuttle service between the convention center and participating conference hotels. Shuttle schedule information will be made available on the ASH conference website and also posted in the lobby of participating hotels.

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma.

There is no fee to participate in this hybrid event. For the in-person symposium in New Orleans preregistration is required as seating is limited.
​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

In-person Registration for clinicians in practice »
 
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

In-person Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.